CDK5 knockdown prevents hippocampal degeneration and cognitive dysfunction produced by cerebral ischemia

Journal of Cerebral Blood Flow and Metabolism

Volumn 35, Issue 12, 2015, Pages 1937-1949

  Gutiérrez Vargas, Johana A ^a   Múnera, Alejandro ^b   Cardona Gómez, Gloria P ^a  

^a UNIVERSIDAD DE ANTIOQUIA   (Colombia)

^b UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

Author keywords

CDK5 RNAi; cerebral ischemia; cognitive disorder; gene therapy; neuroprotection

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE 5; MICROTUBULE ASSOCIATED PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE; CARBON DIOXIDE; CDK5 PROTEIN, RAT; OXYGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BRAIN ISCHEMIA; CARBON DIOXIDE TENSION; COGNITIVE DEFECT; CONTROLLED STUDY; DEGENERATION; DOWN REGULATION; ENZYME ACTIVATION; GENE SILENCING; GENE TARGETING; GENE THERAPY; HIPPOCAMPUS; IMMUNOREACTIVITY; LEARNING DISORDER; MACROGLIA; MALE; MEMORY DISORDER; MICROGLIA; MIDDLE CEREBRAL ARTERY OCCLUSION; MOTOR PERFORMANCE; NERVE CELL PLASTICITY; NONHUMAN; OXYGEN TENSION; PH; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RNA INTERFERENCE; TAUOPATHY; ANIMAL; BLOOD; BRAIN CHEMISTRY; CEREBROVASCULAR ACCIDENT; COGNITION DISORDERS; COMPLICATION; DRUG EFFECTS; GENETICS; LEARNING; LEARNING DISORDERS; MAZE TEST; MEMORY DISORDERS; METABOLISM; MOVEMENT DISORDERS; NERVE DEGENERATION; PATHOLOGY; PSYCHOLOGY;

ANIMALS; BLOOD PRESSURE; BRAIN CHEMISTRY; BRAIN ISCHEMIA; CARBON DIOXIDE; COGNITION DISORDERS; CYCLIN-DEPENDENT KINASE 5; GENE KNOCKDOWN TECHNIQUES; HIPPOCAMPUS; HYDROGEN-ION CONCENTRATION; LEARNING DISORDERS; MALE; MAZE LEARNING; MEMORY DISORDERS; MOVEMENT DISORDERS; NERVE DEGENERATION; OXYGEN; RATS; REVERSAL LEARNING; RNA INTERFERENCE; STROKE;

EID: 84948717558     PISSN: 0271678X     EISSN: 15597016     Source Type: Journal    
DOI: 10.1038/jcbfm.2015.150     Document Type: Article

References (40)

1. Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010; 67: 181-198.
2. Grotta J, Marler J. Intravenous rt-PA: a tenth anniversary reflection. Surg Neurol. 2007; 68: S12-S16.
3. Pan J, Konstas AA, Bateman B, Ortolano GA, Pile-Spellman J. Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies. Neuroradiology. 2007; 49: 93-102.
4. Chen RL, Balami JS, Esiri MM, Chen LK, Buchan AM. Ischemic stroke in the elderly: an overview of evidence. Nat Rev Neurol. 2010; 6: 256-265.
5. Aggarwal NT, Decarli C. Vascular dementia: emerging trends. Semin Neurol. 2007; 27: 66-77.
6. Wen Y, Yang S, Liu R, Simpkins JW. Transient cerebral ischemia induces sitespecific hyperphosphorylation of tau protein. Brain Res. 2004; 1022: 30-38.
7. Barnett DG, Bibb JA. The role of Cdk5 in cognition and neuropsychiatric and neurological pathology. Brain Res Bull. 2011; 85: 9-13.
8. Dhavan R, Tsai LH A decade of CDK5. Nat Rev Mol Cell Biol. 2001; 2: 749-759.
9. Fischer PM. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors. Curr Opin Drug Discov Devel. 2001; 4: 623-634.
10. Menn B, Bach S, Blevins TL, Campbell M, Meijer L, Timsit S. Delayed treatment with systemic (S)-roscovitine provides neuroprotection and inhibits in vivo CDK5 activity increase in animal stroke models. PLoS One. 2010; 5: e12117.
11. Sielecki TM, Boylan JF, Benfield PA, Trainor GL. Cyclin-dependent kinase inhibitors: useful targets in cell cycle regulation. J Med Chem. 2000; 43: 1-18.
12. Glicksman MA, Cuny GD, Liu M, Dobson B, Auerbach K, Stein RL, et al. New approaches to the discovery of cdk5 inhibitors. Curr Alzheimer Res. 2007; 4: 547-549.
13. Meyer DA, Torres-Altoro MI, Tan Z, Tozzi A, Di Filippo M, DiNapoli V, et al. Ischemic stroke injury is mediated by aberrant Cdk5. J Neurosci. 2014; 34: 8259-8267.
14. Khvorova A, Reynolds A, Jayasena SD. Functional siRNAs and miRNAs exhibit strand bias. Cell. 2003; 115: 209-216.
15. Gonzalez-Alegre P. Therapeutic RNA interference for neurodegenerative diseases: From promise to progress. Pharmacol Ther. 2007; 114: 34-55.
16. Cespedes-Rubio A, Jurado FW, Cardona-Gomez GP. p120 catenin/alphaN-catenin are molecular targets in the neuroprotection and neuronal plasticity mediated by atorvastatin after focal cerebral ischemia. J Neurosci Res. 2010; 88: 3621-3634.
17. Piedrahita D, Hernandez I, Lopez-Tobon A, Fedorov D, Obara B, Manjunath BS, et al. Silencing of CDK5 reduces neurofibrillary tangles in transgenic alzheimer's mice. J Neurosci. 2010; 30: 13966-13976.
18. Garcia JH, Wagner S, Liu KF, Hu XJ. Neurological deficit and extent of neuronal necrosis attributable to middle cerebral artery occlusion in rats. Statistical validation. Stroke. 1995; 26: 627-634.
19. Rivlin AS, Tator CH. Objective clinical assessment of motor function after experimental spinal cord injury in the rat. J Neurosurg. 1977; 47: 577-581.
20. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods. 1984; 11: 47-60.
21. Joshi CN, Jain SK, Murthy PS. An optimized triphenyltetrazolium chloride method for identification of cerebral infarcts. Brain Res Brain Res Protoc. 2004; 13: 11-17.
22. Roulston CL, Callaway JK, Jarrott B, Woodman OL, Dusting GJ. Using behaviour to predict stroke severity in conscious rats: post-stroke treatment with 3', 4'-dihydroxyflavonol improves recovery. Eur J Pharmacol. 2008; 584: 100-110.
23. Gutierrez-Vargas JA, Munoz-Manco JI, Garcia-Segura LM, Cardona-Gomez GP. GluN2B N-methyl-D-Aspartic acid receptor subunit mediates atorvastatin-Induced neuroprotection after focal cerebral ischemia. J Neurosci Res. 2014; 92: 1529-1548.
24. Johanna GV, Fredy CA, David VC, Natalia MV, Angel CR, Patricia CG. Rac1 activity changes are associated with neuronal pathology and spatial memory long-Term recovery after global cerebral ischemia. Neurochem Int. 2010; 57: 762-773.
25. Sweatt JD. The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory. J Neurochem. 2001; 76: 1-10.
26. Hu Y, Russek SJ. BDNF and the diseased nervous system: a delicate balance between adaptive and pathological processes of gene regulation. J Neurochem. 2008; 105: 1-17.
27. Patrick GN, Zhou P, Kwon YT, Howley PM, Tsai LH. p35, the neuronal-specific activator of cyclin-dependent kinase 5 (Cdk5) is degraded by the ubiquitinproteasome pathway. J Biol Chem. 1998; 273: 24057-24064.
28. Ahlijanian MK, Barrezueta NX, Williams RD, Jakowski A, Kowsz KP, McCarthy S, et al. Hyperphosphorylated tau and neurofilament and cytoskeletal disruptions in mice overexpressing human p25, an activator of cdk5. Proc Natl Acad Sci USA. 2000; 97: 2910-2915.
29. Koumura A, Nonaka Y, Hyakkoku K, Oka T, Shimazawa M, Hozumi I, et al A novel calpain inhibitor, ((1S)-1((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl) amino)carbonyl)-3-met hylbutyl) carbamic acid 5-methoxy-3-oxapentyl ester, protects neuronal cells from cerebral ischemia-induced damage in mice. Neuroscience. 2008; 157: 309-318.
30. Barros SA, Gollob JA. Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev. 2012; 64: 1730-1737.
31. Castro-Alvarez JF, Uribe-Arias SA, Kosik KS, Cardona-Gomez GP. Long- And shortterm CDK5 knockdown prevents spatial memory dysfunction and tau pathology of triple transgenic Alzheimer's mice. Front Aging Neurosci. 2014; 6: 243.
32. Zhang J, Wang Y, Zhu P, Wang X, Lv M, Feng H. siRNA-mediated silence of protease-Activated receptor-1 minimizes ischemic injury of cerebral cortex through HSP70 and MAP2. J Neurol Sci. 2012; 320: 6-11.
33. Hosp JA, Luft AR. Cortical plasticity during motor learning and recovery after ischemic stroke. Neural Plast. 2011; 2011: 871296.
34. Nadel L, Hupbach A, Gomez R, Newman-Smith K. Memory formation, consolidation and transformation. Neurosci Biobehav Rev. 2012; 36: 1640-1645.
35. Hawasli AH, Benavides DR, Nguyen C, Kansy JW, Hayashi K, Chambon P, et al. Cyclin-dependent kinase 5 governs learning and synaptic plasticity via control of NMDAR degradation. Nat Neurosci. 2007; 10: 880-886.
36. Posada-Duque RA, Lopez-Tobon A, Piedrahita D, Gonzalez-Billault C, Cardona-Gomez GP. p35 and Rac1 underlie the neuroprotection and cognitive improvement induced by CDK5 silencing. J Neurochem 201510.1111/jnc.13127.
37. Sundaram JR, Poore CP, Sulaimee NH, Pareek T, Asad AB, Rajkumar R, et al. Specific inhibition of p25/Cdk5 activity by the Cdk5 inhibitory peptide reduces neurodegeneration in vivo. J Neurosci. 2013; 33: 334-343.
38. Chen A, Xiong LJ, Tong Y, Mao M. The neuroprotective roles of BDNF in hypoxic ischemic brain injury. Biomed Rep. 2013; 1: 167-176.
39. Alonso M, Medina JH, Pozzo-Miller L. ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. Learn Mem. 2004; 11: 172-178.
40. van der Worp HB, van Gijn J. Clinical practice. Acute ischemic stroke. N Engl J Med. 2007; 357: 572-579.